Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages ::>

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link
The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:
Type of Payload
  • Type of Linker
  • VC
  • Sulfo-SPDB
  • SMCC
  • VA
  • Hydrazone
  • Others
Target Indication
  • Breast cancer
  • Lymphoma
  • Leukemia
  • Urothelial cancer
  • Lung cancer
  • Ovarian cancer
  • Others
Target Antigen
  • CD30
  • HER2
  • CD22
  • CD33
  • Others
Technology Providers
  • Seattle Genetics
  • ImmunoGen
  • StemCentRx
  • Immunomedics
  • Others

Key Geographical Regions
North America
Asia Pacific
The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain: 
Bristol Myers Squibb
Trillium Therapeutics
Table of Contents
1. Preface

2. Executive Summary

3. Introduction

Market Overview

5. Company and Drug Profiles

6. Key Therapeutic Areas

7. Key Opinion Leaders

8. Target Competitiveness Analysis

9. Partnerships and Collaborations

10. Funding and Investment Analysis

11. Patent Analysis

12. Academic Grants

13. Key Commercialization Strategies
14. Promotional Analysis
15. Combination Therapies
16. Novel Conjugation Technology Platforms
17. Assessment of Non-Clinical Data, First in Human Dosing
18. Cost Price Analysis
19. Case Study: Contract Manufacturing of ADC
20. Case Study: Companion Diagnostics for ADC Therapeutic
21. Market Forecast and Opportunity Analysis
22. Swot Analysis

23. Conclusion
24. Executive Insights
25. Appendix 1: Tabulated Data
To purchase a copy, please visit
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415  

You may also like


No comments yet... Be the first to leave a reply! Login here

0 Karma
1448 Posts

Made with by Mamby